Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Opportunities to Optimize Cancer Policies Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Opening Session Panel Discussion

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Apr

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Opening Session Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Tracking Biological Age Changes Gives Insights Into Cancer Prognosis

Neoadjuvant Durvalumab and Chemotherapy in Triple-Negative Breast Cancer: Long-Term Follow-Up of GeparNuevo Trial

Global Review Shows Impact of Exposure to Air Pollution on Cancer Risk and Mortality

Do Political Beliefs Shape Views on Clinical Trials in Cancer?

RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer